


Ticarcillin

Cat. No.:	HY-139805
CAS No.:	34787-01-4
Molecular Formula:	C ₁₅ H ₁₆ N ₂ O ₆ S ₂
Molecular Weight:	384.43
Target:	Antibiotic; Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ticarcillin is a semisynthetic, extended-spectrum, carboxypenicillin antibacterial agent, and is active against gram-positive cocci, including streptococci and staphylococci. Ticarcillin is also effective against most gram-negative organisms, including <i>Pseudomonas aeruginosa</i> . Ticarcillin can be used in lower respiratory tract infections, skin and skin structure infections, urinary tract infections, and intraabdominal infections research ^{[1][2][3]} .											
IC₅₀ & Target	β-lactam											
In Vitro	<p>Ticarcillin treatment (10 mg/L; 18 h) shows antibacterial activities^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Ps. aeruginosa</td> </tr> <tr> <td>Concentration:</td> <td>10 mg/L</td> </tr> <tr> <td>Incubation Time:</td> <td>18 hours</td> </tr> <tr> <td>Result:</td> <td>Showed the MIC for Ticarcillin against strain between 6.3-12.5 mg/L.</td> </tr> </table>		Cell Line:	Ps. aeruginosa	Concentration:	10 mg/L	Incubation Time:	18 hours	Result:	Showed the MIC for Ticarcillin against strain between 6.3-12.5 mg/L.		
Cell Line:	Ps. aeruginosa											
Concentration:	10 mg/L											
Incubation Time:	18 hours											
Result:	Showed the MIC for Ticarcillin against strain between 6.3-12.5 mg/L.											
In Vivo	<p>Ticarcillin (Subcutaneous injection; 50, 100, 200 mg/kg; once) treatment shows a dose-dependent antibacterial effect^[2]. Ticarcillin (Subcutaneous injection; 50, 100, 200 mg/kg; once) treatment shows excellent pharmacokinetic assessment^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Swiss type male mice injected with <i>Ps. aeruginosa</i>^[2]</td> </tr> <tr> <td>Dosage:</td> <td>50, 100, 200 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection; 50, 100, 200 mg/kg; once</td> </tr> <tr> <td>Result:</td> <td>Increased effect significantly (0.001 < P < 0.0025) with increasing dose.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Swiss type male mice injected with <i>Ps. aeruginosa</i>^[2]</td> </tr> </table>		Animal Model:	Swiss type male mice injected with <i>Ps. aeruginosa</i> ^[2]	Dosage:	50, 100, 200 mg/kg	Administration:	Subcutaneous injection; 50, 100, 200 mg/kg; once	Result:	Increased effect significantly (0.001 < P < 0.0025) with increasing dose.	Animal Model:	Swiss type male mice injected with <i>Ps. aeruginosa</i> ^[2]
Animal Model:	Swiss type male mice injected with <i>Ps. aeruginosa</i> ^[2]											
Dosage:	50, 100, 200 mg/kg											
Administration:	Subcutaneous injection; 50, 100, 200 mg/kg; once											
Result:	Increased effect significantly (0.001 < P < 0.0025) with increasing dose.											
Animal Model:	Swiss type male mice injected with <i>Ps. aeruginosa</i> ^[2]											

Dosage: 50, 100, 200 mg/kg
Administration: Subcutaneous injection; 50, 100, 200 mg/kg; once

Result:

	Dose (mg/kg)	AUC ^a (mg/kg)	K _{el} ^b (h ⁻¹)	T _{1/2} (min)
Ticarcillin	50	8.76 (0.72)	1.57 (0.18)	26
	100	26.14 (0.60)	1.53 (0.11)	27
	200	54.56 (2.90)	1.47 (0.12)	28

CUSTOMER VALIDATION

- Antimicrob Agents Chemother. 2023 May 18;e0160322.
- Microbiol Spectr. 2023 Apr 24;e0069223.
- Microbiol Spectr. 2022 Dec 8;e0303822.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Cecile Formosa, et al. Nanoscale effects of antibiotics on *P. aeruginosa*. *Nanomedicine*. 2012 Jan;8(1):12-6.
- [2]. G B van der Voet, et al. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice. *J Antimicrob Chemother*. 1985 Nov;16(5):605-13.
- [3]. Oriël Spierer, et al. Comparative activity of antimicrobials against *Pseudomonas aeruginosa*, *Achromobacter xylosoxidans* and *Stenotrophomonas maltophilia* keratitis isolates. *Br J Ophthalmol*. 2018 May;102(5):708-712.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA